BOCA RATON, Fla., July 6 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals
(Nasdaq: NABI) will issue a press release highlighting the second quarter
financial results on Tuesday, July 19, 2005, at market close. The company
will also host a live webcast and audio conference call at 4:30 p.m. ET. Nabi
Biopharmaceuticals' management will discuss the second quarter results and
expectations.
The live webcast can be accessed at: http://audioevent.mshow.com/245334
or via the Nabi Biopharmaceuticals website at http://www.nabi.com . If you do
not have internet access, the domestic call-in number is 877-569-0953,
conference code 7442676 and the international call-in number is 706-634-4967,
conference code 7442676. An audio replay will be available for domestic
callers at 800-642-1687, conference code 7442676, and for international
callers at 706-645-9291, conference code 7442676.
Following the webcast, an archived version of the webcast will be
available at the same internet address through July 26, 2005. The audio
replay will also be available through July 26, 2005. The press release will
be available on the company's website at: http://www.nabi.com .
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are poised to capture large, commercial opportunities in our
four core business areas: Gram-positive bacterial infections, hepatitis,
kidney disease (nephrology), and nicotine addiction. We have three products on
the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune
Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a
number of products in various stages of clinical and preclinical development.
The company filed its Marketing Authorization Application in Europe for its
candidate product StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate
Vaccine] in December 2004. The application was accepted for review in January
2005. StaphVAX is currently in a confirmatory Phase III clinical trial in the
United States. StaphVAX is designed to prevent the most dangerous and
prevalent strains of Staphylococcus aureus bacterial infections. S. aureus
bacteria are a major cause of hospital-acquired infections and are becoming
increasingly resistant to antibiotics. The company's other products in
development include Altastaph(TM) [Staphylococcus aureus Immune Globulin
Intravenous (Human)], an antibody for prevention and treatment of S. aureus
infections, NicVAX(TM) [Nicotine Conjugate Vaccine], a vaccine to treat
nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an
antibody for preventing hepatitis C virus re-infection in liver transplant
patients. For additional information on Nabi Biopharmaceuticals, please visit
our website at: http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
Audio:http://audioevent.mshow.com/245334
CONTACT:
Constance Bienfait, Vice President, Investor
Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
